Clinical Trials Browser

Phase 1/2 × Metastatic Pancreatic Ductal Adenocarcinoma × 90 days × Clear all

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma